GSK will invest $30 billion (£22 billion) across the US over the next five years in research and development and supply chain infrastructure, the company has announced. The investment includes a new $1.2 billion (£880 million) investment in advanced manufacturing facilities and AI and advanced digital technologies, delivering new next-generation biopharma factories and laboratories in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!